company background image
NTRA

Natera NasdaqGS:NTRA Stock Report

Last Price

US$47.11

Market Cap

US$5.4b

7D

-7.4%

1Y

32.9%

Updated

31 May, 2023

Data

Company Financials +

NTRA Stock Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

NTRA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Natera, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Natera
Historical stock prices
Current Share PriceUS$47.11
52 Week HighUS$59.75
52 Week LowUS$30.46
Beta1.21
1 Month Change-10.23%
3 Month Change-16.58%
1 Year Change32.85%
3 Year Change8.67%
5 Year Change276.58%
Change since IPO107.17%

Recent News & Updates

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16
Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18
Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Recent updates

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16
Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18
Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Natera: Cracks In The Bearish Trade

Oct 10

Natera gains after publication of data on transplant rejection assessment test

Oct 04

Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?

Sep 13
Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?

Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer

Jul 18

Nothing Compelling About Natera

Jun 24

Is Natera (NASDAQ:NTRA) Weighed On By Its Debt Load?

May 30
Is Natera (NASDAQ:NTRA) Weighed On By Its Debt Load?

Despite Lacking Profits Natera (NASDAQ:NTRA) Seems To Be On Top Of Its Debt

Feb 21
Despite Lacking Profits Natera (NASDAQ:NTRA) Seems To Be On Top Of Its Debt

Natera: Standout Buy In Diagnostic Testing Materials, Now Seen By Market-Makers

Dec 24

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Nov 08
Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Shareholder Returns

NTRAUS BiotechsUS Market
7D-7.4%-2.2%1.0%
1Y32.9%11.4%-0.2%

Return vs Industry: NTRA exceeded the US Biotechs industry which returned 10% over the past year.

Return vs Market: NTRA exceeded the US Market which returned -0.1% over the past year.

Price Volatility

Is NTRA's price volatile compared to industry and market?
NTRA volatility
NTRA Average Weekly Movement6.7%
Biotechs Industry Average Movement11.0%
Market Average Movement6.5%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: NTRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NTRA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20032,988Steve Chapmanhttps://www.natera.com

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company’s products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test.

Natera, Inc. Fundamentals Summary

How do Natera's earnings and revenue compare to its market cap?
NTRA fundamental statistics
Market CapUS$5.38b
Earnings (TTM)-US$546.14m
Revenue (TTM)US$867.85m

6.2x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTRA income statement (TTM)
RevenueUS$867.85m
Cost of RevenueUS$501.17m
Gross ProfitUS$366.68m
Other ExpensesUS$912.82m
Earnings-US$546.14m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.78
Gross Margin42.25%
Net Profit Margin-62.93%
Debt/Equity Ratio55.7%

How did NTRA perform over the long term?

See historical performance and comparison